Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390911 | 1.00 | DPP4 (0.37) | DPP4DPP8NPC1RAB9AGFER | |
| SCHEMBL29669299 | 0.86 | DPP4 (0.35) | DPP4DPP8DYRK1A | |
| SCHEMBL24463371 | 0.86 | DPP4 (0.35) | DPP4DPP8DYRK1A | |
| SCHEMBL30490152 | 0.79 | DPP4 (0.39) | DPP4DPP8NPC1RAB9AGFER | |
| SCHEMBL26790803 | 0.79 | DPP4 (0.38) | DPP4DPP8 | |
| SCHEMBL24463137 | 0.79 | DPP4 (0.39) | DPP4DPP8NPC1RAB9AGFER | |
| SCHEMBL24463141 | 0.77 | DPP4 (0.38) | DPP4DPP8DYRK1A | |
| SCHEMBL24463280 | 0.75 | DPP4 (0.41) | DPP4DPP8DYRK1A | |
| SCHEMBL30461512 | 0.74 | JAK1 (0.33) | GAAHSD17B10 | |
| SCHEMBL24463507 | 0.74 | JAK1 (0.33) | GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | KINNATE BIOPHARMA INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | DPP4 2192/4885DPP8 1200/4885NPC1 1043/4885 |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | DPP4 2192/4885DPP8 1200/4885NPC1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.